The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients

BACKGROUND: Despite the undeniable benefit of tamoxifen therapy for ER-positive breast cancer patients, approximately one-third of those patients either do not respond to tamoxifen or develop resistance. Thus, it is a crucial step to identify novel, reliable, and easily detectable biomarkers indicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamzam, Yomna, Abdelmonem Zamzam, Yosra, Aboalsoud, Marwa, Harras, Heba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460385/
https://www.ncbi.nlm.nih.gov/pubmed/34567804
http://dx.doi.org/10.1155/2021/9947540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460385/
https://www.ncbi.nlm.nih.gov/pubmed/34567804
http://dx.doi.org/10.1155/2021/9947540

Ejemplares similares